Bicycle Therapeutics (BCYC) Long-Term Deferred Tax (2022 - 2023)
Bicycle Therapeutics posted quarterly Long-Term Deferred Tax of $88.6 million for Q4 2023, up 980.45% year-on-year from $8.2 million in Q4 2022, and up 980.45% on a QoQ basis from $8.2 million in Q4 2022.
Bicycle Therapeutics (BCYC) has 2 years of Long-Term Deferred Tax data on file, last reported at $88.6 million in Q4 2023.
- For the quarter ending Q4 2023, Long-Term Deferred Tax rose 980.45% year-over-year to $88.6 million; the trailing twelve-month figure through Dec 2023 stood at $88.6 million (up 980.45% YoY), and the FY2023 full-year result was $88.6 million, up 980.45% from the prior year.
- Long-Term Deferred Tax for Q4 2023 stood at $88.6 million, up from $8.2 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $88.6 million in Q4 2023 and bottomed at $8.2 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Bicycle Therapeutics | 326.82 Mn | 326.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 88.55 Mn |
| Dec 31, 2022 | 8.20 Mn |